BHC
Bausch Health Companies Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
None.
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q4 2018 | 31Q | $27 | $5.34 | -80% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $5.53 | $5.34 | -3% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $5.53 | $5.34 | -3% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $5.53 | $5.34 | -3% |
| Renaissance Technologies | Q4 2024(8Q snapshot) | 6Q | $8.78 | $5.34 | -39% |
| Two Sigma Investments | Q4 2024(8Q snapshot) | 6Q | $8.76 | $5.34 | -39% |
| Point72 Asset Management re-entered | Q2 2025(8Q snapshot) | 4Q | $4.60 | $5.34 | +16% |
| AQR Capital Management | Q1 2026(8Q snapshot) | 1Q | $5.99 | $5.34 | -11% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Third Point | Q4 2025 | Q2 2026 | → $5.42 | -14% |
| Maverick Capital 4× in & out | Q3 2024 | Q1 2025 | → $6.16 | +11% |
| Glenview Capital 4× in & out | Q3 2024 | Q4 2024 | → $8.76 | +58% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Bausch Health Companies Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 26, 2026 — the most recent Form 4 on file — not from today.
- Form 40000885590-26-000083May 26, 2026
- Form 40000885590-26-000082May 26, 2026
- Form 40000885590-26-000081May 26, 2026
- Form 40000885590-26-000080May 26, 2026
- Form 40000885590-26-000079May 26, 2026
- Form 40000885590-26-000078May 26, 2026
- Form 40000885590-26-000077May 26, 2026
- Form 40000885590-26-000076May 26, 2026
- Form 40000885590-26-000075May 26, 2026
- Form 40000885590-26-000063May 20, 2026
- Form 40000885590-26-000047Apr 2, 2026
- Form 40000885590-26-000045Apr 2, 2026
- Form 40000885590-26-000043Apr 2, 2026
- Form 40000885590-26-000041Mar 3, 2026
- Form 40000885590-26-000039Mar 3, 2026
Fundamentals
XBRL · Bausch Health Companies Inc.Annual figures sourced directly from Bausch Health Companies Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Bausch Health Companies Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 19, 2026
- 10-QQuarterly reportApr 30, 2026
- 8-KMaterial eventApr 29, 2026
- DEF 14AProxy statementApr 8, 2026
- 8-KMaterial eventMar 2, 2026
- 10-KAnnual reportFeb 19, 2026
- 8-KMaterial eventFeb 18, 2026
- 8-KMaterial eventJan 23, 2026
- 8-KMaterial eventJan 13, 2026
- 8-KFORM 8-KJan 2, 2026
- 8-KMaterial eventDec 29, 2025
- 8-KMaterial eventDec 23, 2025
- 8-KFORM 8-KDec 12, 2025
- 8-KMaterial eventDec 9, 2025
- 8-KMaterial eventNov 24, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| AQR Capital Management | Q1 2026 | open | $5.99 | $5.34 | -11% |
| Third Point | Q4 2025 | Q2 2026 | $6.28 | $5.42 | -14% |
| Point72 Asset Management | Q4 2025 | open | $6.28 | $5.34 | -15% |
| Point72 Asset Management | Q2 2025 | Q3 2025 | $4.60 | $7.51 | +63% |
| Two Sigma Investments | Q4 2024 | open | $8.76 | $5.34 | -39% |
| Renaissance Technologies | Q4 2024 | open | $8.78 | $5.34 | -39% |
| Citadel Advisors | Q3 2024 | open | $5.53 | $5.34 | -3% |
| Glenview Capital | Q3 2024 | Q4 2024 | $5.53 | $8.76 | +58% |
| D.E. Shaw | Q3 2024 | open | $5.53 | $5.34 | -3% |
| Millennium Management | Q3 2024 | open | $5.53 | $5.34 | -3% |
| Maverick Capital | Q3 2024 | Q1 2025 | $5.53 | $6.16 | +11% |
| Maverick Capital | Q4 2023 | Q1 2024 | $6.79 | $8.43 | +24% |
| Glenview Capital | Q3 2023 | Q4 2023 | $8.42 | $6.79 | -19% |
| Glenview Capital | Q1 2023 | Q2 2023 | $7.53 | $6.03 | -20% |
| Maverick Capital | Q4 2022 | Q1 2023 | $7.14 | $7.53 | +5% |
| Bridgewater Associates | Q1 2021 | open | $31 | $5.11 | -84% |
| Glenview Capital | Q4 2018 | Q3 2022 | $26 | $6.20 | -77% |
| Maverick Capital | Q4 2018 | Q3 2022 | $26 | $6.28 | -76% |
| Bridgewater Associates | Q4 2018 | Q3 2020 | $27 | $17 | -35% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.